newsfilter
← Latest News
Business Wire·

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

- The Phase 2 GAD study has enrolled 36 participants to evaluate the safety and efficacy of CYB004 at 12 weeks after first dose - - Reaffirms top-line data guidance for Q1 2026 - Cybin Inc. (NYSE:CYBN) (Cboe